As part of the company’s ongoing support of maternal and neonatal health, AMAG Pharmaceuticals, Inc. today announced it has awarded four grants totaling $300,000 to independent researchers in the field.
The 2017 grant recipients were selected by an independent external review panel of several maternal fetal medicine (MFM) specialists. The panel was chaired by George Saade, MD, Professor, Obstetrics/Gynecology and Cell Biology at The University of Texas Medical Branch.
“Research is an important way to advance our understanding of preterm birth, which we hope will ultimately lead to the reduction of babies born too early in our country,” said Dr. Saade. “The review committee was extremely pleased with the number, quality and novelty of the applications this year. Support from organizations like AMAG is critical, enabling these researchers to continue their work and expand our knowledge about preterm birth.”
Jacqueline Parchem, MD is an assistant professor at the McGovern Medical School, University of Texas Health Science Center at Houston in the Department of Obstetrics, Gynecology & Reproductive Sciences who is researching the role of amniotic fluid exosomes in fetal development and placental membrane health.
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of maternal and women’s health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
Source – AMAG Pharmaceuticals